Supplement Figure S3. Inhibition of PC3 prostate cancer cell growth in mice after knockdown ADAM9 expression. (a) Scheme illustration of subcutaneous inoculation of PC3\textsubscript{pSM2C} and PC3\textsubscript{shADAM9} in same mice. PC3\textsubscript{pSM2C} was implanted in the left site and PC3\textsubscript{shADAM9} in the right site of lower back of same mice. (b) Bioluminescence imaging obtained at day-30 post inoculation. Only two mice revealed a weak bioluminescence signal on the right site of PC3\textsubscript{shADAM9} (black arrow). (c) On day 15, signal was first observed at the PC3\textsubscript{pSM2C} implant site in 50\% of the mice, increasing to 90\% on day 25. The number of mice with a signal at the PC3\textsubscript{shADAM9} implant site remained at 10\% (mice, n=20; ** p ≤ 0.001). (d) Tumor volume was measured every 5 days starting at day 15 and ending at day 60. Tumor volume was 281 ± 91 mm\textsuperscript{3} in PC3\textsubscript{pSM2C} and 140 ± 37 mm\textsuperscript{3} in PC3\textsubscript{shADAM9} on day 60 (means ± SD) (*p ≤ 0.05 one-way ANOVA).